AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

FARON PHARMACEUTICALS OY

Major Shareholding Notification Oct 21, 2025

7635_mrq_2025-10-21_4accb367-ef90-40b4-99c7-80e7fef322bd.html

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

Faron Pharmaceuticals

21 Oct 2025 13:10 UTC


FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | October 21, 2025 at 16:10:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: Change due the Private Placement
3. Details of person subject to the notification obligation iv
Name Timo Syrjälä
City and country of registered office (if applicable) Monaco
4. Full name of shareholder(s) (if different from 3.) v
Name Acme Investments SPF Sarl
City and country of registered office (if applicable) Luxembourg
5. Date on which the threshold was crossed or reached vi: 20.10.2025
6. Date on which issuer notified (DD/MM/YYYY): 20.10.2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Resulting situation on the date on which threshold was crossed or reached 15,18
Position of previous notification (if

applicable)
15,00 (14,997%)
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type ofshares

ISIN code (if possible)
Number of voting rights ix
Direct

(DTR5.1)
Indirect

(DTR5.2.1)
Direct

(DTR5.1)
FI4000153309 5.296.452 11.928.944
SUBTOTAL 8. A 17.225.396
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expirationdate x Exercise/Conversion Period xi
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expirationdate x Exercise/Conversion Period xi Physical or cash

Settlement xii
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct) 4,67% 4,67%
Acme Investments SPF Sarl (Indirect) 10,51% 10,51%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Acme Investment SPF Sarl is fully owned by Timo Syrjälä
Place of completion Monaco
Date of completion 20.10.2025

MFN is a regulatory news distribution service and it is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. The service is built to easily manage all the tasks of news distribution for listed companies.

For further information, please contact [email protected] or visit Modular Finance.

View the source version on MFN: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Talk to a Data Expert

Have a question? We'll get back to you promptly.